FDA Approves Glaxo's (GSK) TYKERB in Combination With Xeloda for the Treatment of Advanced or Metastatic Breast Cancer
More News related to GSK
- InvestorSoup.com Stock Alerts on: Evergreen Solar, GlaxoSmithKline, Intrepid Potash, Discovery Labs and Nissan
- Piper Jaffray Downgrades Phase Forward (PFWD) to Neutral; Lack of Near-Term Catalysts
- Phase Forward (PFWD) Signs Multi-Yr, Multi-Million Dollar Contract with GlaxoSmithKline (GSK)
- Launch of Targeted Agents and Increased Use of Maintenance Therapy Will Drive the Non-Small-Cell Lung Cancer Drug Market to Nearly Triple to Almost $10 Billion in 2018
- Society of Hispanic Professional Engineers Elects New National Board With Raytheon's Manny Hernandez as President
More News related to FDA
- Caraco Pharmaceutical Laboratories (CPD) Announces Its Reducing Its Workforce By 350 Employees
- Covidien (COV) Announces Health Canada Approval for its Generic Myocardial Perfusion Imaging Kit
- CombinatoRx (CRXX) Publishes Research Demonstrating Improved Selectivity Through Synergistic Combinations
- Spectrum Pharmac (SPPI) Receives Complete Response Letter from FDA for Zevalin
- Lilly (LLY) Receives Fourth FDA Approval for ALIMTA
UPDATE - GlaxoSmithKline plc (NYSE: GSK) announced today that the United States Food and Drug Administration (FDA) approved TYKERB (lapatinib), in combination with Xeloda, for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. It is the first targeted, once-daily oral treatment option for this patient population. TYKERB was granted Priority Review by the FDA in November 2006.
"The approval of TYKERB is an important milestone in our commitment to become a major oncology company that focuses on scientific innovation and genuine patient needs," said Chris Viehbacher, President, US Pharmaceuticals at GSK. "Our rich pipeline of oncology medicines underscores our commitment to cancer patients. This commitment extends to programs to help ensure that women who may benefit from TYKERB will have access to it."
GlaxoSmithKline has confirmed that its new treatment TYKERB will be available through Commitment to Access, the company's program that provides low income patients with access to GSK products used in an outpatient setting in the United States.
Related Categories
FDAStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
